Jeff X. Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeff X. Zhou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Chang Hoon Lee
Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, MD 20852
2 shared publications- Herbert C. Morse
Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases and
2 shared publications Hongsheng Wang
Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, MD 20852
2 shared publicationsLei Jiang
B Department of Pathology , Ningbo University School of Medicine , Ningbo , China
2 shared publications- Amrie C. Grammer
AMPEL BioSolutions LLC and the RILITE Research Institute, Charlottesville, Virginia, United States
1 shared publication Boris van der Zouwen
1 shared publication
Latest Publications
- 20 June 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (1) , 114-120
High expression of INHBA is an adverse prognostic factor forde novoacute myeloid leukemia
Inhibin-β A (INHBA) is a ligand of the transforming growth factor β superfamily and associated with tumorigenesis and tumor progression in solid tumors. In this study, we investigated the expression levels and clinical significance of INHBA in acute myeloid leukemia (AML). The results showed that high expression of INHBA was significantly correlated with elderly age (>60 years) (p = .038), adverse cytogenetic risks (p = .034), negative NPM1 mutation (p = .016), positive FLT3 internal tandem duplications (p = .011), and low hemoglobin levels (p = .04). Patients with high levels of INHBA had poor responses to therapies as indicated by lower complete remission rate (p = .004), higher early death rate (p = .018), and shorter relapse-free survival (p = .04) and overall survival (p = .003). Moreover, multivariate analysis showed that high expression of INHBA was an independent adverse prognostic factor for AML. Taken together, our study suggested that high expression of INHBA was an adverse prognostic factor for de novo AML.
- 20 June 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (1) , 114-120
High expression of INHBA is an adverse prognostic factor forde novoacute myeloid leukemia
Inhibin-β A (INHBA) is a ligand of the transforming growth factor β superfamily and associated with tumorigenesis and tumor progression in solid tumors. In this study, we investigated the expression levels and clinical significance of INHBA in acute myeloid leukemia (AML). The results showed that high expression of INHBA was significantly correlated with elderly age (>60 years) (p = .038), adverse cytogenetic risks (p = .034), negative NPM1 mutation (p = .016), positive FLT3 internal tandem duplications (p = .011), and low hemoglobin levels (p = .04). Patients with high levels of INHBA had poor responses to therapies as indicated by lower complete remission rate (p = .004), higher early death rate (p = .018), and shorter relapse-free survival (p = .04) and overall survival (p = .003). Moreover, multivariate analysis showed that high expression of INHBA was an independent adverse prognostic factor for AML. Taken together, our study suggested that high expression of INHBA was an adverse prognostic factor for de novo AML.
- Open Access
- 2 September 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (31) , 31191-31202
Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma
Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma
- 2 September 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (31) , 31191-31202
Open AccessSuppression of CD300A inhibits the growth of diffuse large B-cell lymphoma
Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma
- Open Access
- 8 November 2014
- Published by Wiley in The Anatomical Record
- Vol. 298 (3) , 501-512
Transcription Factor CREB is Involved in CaSR‐mediated Cytoskeleton Gene Expression
Our previous studies illustrated that a steady increase of intracellular calcium concentration ([Ca2+]i) was important for maintaining microtubules (MTs) rearrangement in apoptotic cells. However, little is known about the effect of calcium sensing receptor (CaSR)‐mediated increase in [Ca2+]i on cytoskeleton gene expression. We examined the impact of taxol or CaSR agonist/antagonist on the regulation of [Ca2+]i concentration, cytoskeleton arrangement, phosphorylated CREB and cytoskeleton gene expressions in HeLa cells with dominant negative plasmid of CREB (PM). This study demonstrated that Gdcl3 (a specific CaSR agonist) evoked a rapid increase of [Ca2+]i, formed a rigid bundle of MTs which surrounded the nucleus and decreased the cytoskeleton gene expressions in HeLa cells. These effects were rescued by addition of NPS2390 (a specific CaSR antagonist). Moreover, CaSR activity affected cytoskeleton gene expression through transcription factor CREB. Histoscores of pCREB immunoreactivity in tissues of cervical adenocarcinoma, renal clear cell carcinoma, and diffuse large B‐cell lymphoma were markedly increased compared with non malignant tissue. These data demonstrate, for the first time, that CaSR‐mediated increase in [Ca2+]i probably modulate cytoskeleton organization and gene expression via transcription factor CREB. Anat Rec, 298:501–512, 2015.
- 8 November 2014
- Published by Wiley in The Anatomical Record
- Vol. 298 (3) , 501-512
Open AccessTranscription Factor CREB is Involved in CaSR‐mediated Cytoskeleton Gene Expression
Our previous studies illustrated that a steady increase of intracellular calcium concentration ([Ca2+]i) was important for maintaining microtubules (MTs) rearrangement in apoptotic cells. However, little is known about the effect of calcium sensing receptor (CaSR)‐mediated increase in [Ca2+]i on cytoskeleton gene expression. We examined the impact of taxol or CaSR agonist/antagonist on the regulation of [Ca2+]i concentration, cytoskeleton arrangement, phosphorylated CREB and cytoskeleton gene expressions in HeLa cells with dominant negative plasmid of CREB (PM). This study demonstrated that Gdcl3 (a specific CaSR agonist) evoked a rapid increase of [Ca2+]i, formed a rigid bundle of MTs which surrounded the nucleus and decreased the cytoskeleton gene expressions in HeLa cells. These effects were rescued by addition of NPS2390 (a specific CaSR antagonist). Moreover, CaSR activity affected cytoskeleton gene expression through transcription factor CREB. Histoscores of pCREB immunoreactivity in tissues of cervical adenocarcinoma, renal clear cell carcinoma, and diffuse large B‐cell lymphoma were markedly increased compared with non malignant tissue. These data demonstrate, for the first time, that CaSR‐mediated increase in [Ca2+]i probably modulate cytoskeleton organization and gene expression via transcription factor CREB. Anat Rec, 298:501–512, 2015.
- 1 September 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 183 (5) , 3188-3194
IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells
IFN regulatory factor 8 (IRF8) is a transcription factor that affects the differentiation and function of myeloid, dendritic, and B cells. Herein we report that IRF8 regulates the expression of Mdm2, a suppressor of p53-dependent and -independent apoptosis pathways, in germinal center (GC) B cells. In GC B cells of IRF8-deficient mice, Mdm2 transcripts were greatly down-regulated, and MDM2 protein was poorly expressed in GC of Irf8−/− mice. Small interfering RNA-induced repression of IRF8 in a GC-derived B cell line resulted in decreased expression of MDM2 at the protein level but increased expression of p53 and p21. We found that IRF8 binds to the Mdm2 P2 promoter, and that cotransfection of an IRF8 expression vector with an Mdm2 reporter construct stimulated significant increases in reporter activity. Additionally, transcripts of the p53 target Pmaip1 (Noxa) were significantly increased in IRF8-deficient GC B cells as well as in the IRF8 knockdown B cell line. Finally, cells deficient in IRF8 exhibited growth suppression and increased sensitivity to apoptosis induced by etoposide or IL-21. These results suggest that by regulating MDM2, IRF8 might allow GC B cells to tolerate physiological DNA breaks that otherwise would trigger apoptosis.
- 1 September 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 183 (5) , 3188-3194
IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells
IFN regulatory factor 8 (IRF8) is a transcription factor that affects the differentiation and function of myeloid, dendritic, and B cells. Herein we report that IRF8 regulates the expression of Mdm2, a suppressor of p53-dependent and -independent apoptosis pathways, in germinal center (GC) B cells. In GC B cells of IRF8-deficient mice, Mdm2 transcripts were greatly down-regulated, and MDM2 protein was poorly expressed in GC of Irf8−/− mice. Small interfering RNA-induced repression of IRF8 in a GC-derived B cell line resulted in decreased expression of MDM2 at the protein level but increased expression of p53 and p21. We found that IRF8 binds to the Mdm2 P2 promoter, and that cotransfection of an IRF8 expression vector with an Mdm2 reporter construct stimulated significant increases in reporter activity. Additionally, transcripts of the p53 target Pmaip1 (Noxa) were significantly increased in IRF8-deficient GC B cells as well as in the IRF8 knockdown B cell line. Finally, cells deficient in IRF8 exhibited growth suppression and increased sensitivity to apoptosis induced by etoposide or IL-21. These results suggest that by regulating MDM2, IRF8 might allow GC B cells to tolerate physiological DNA breaks that otherwise would trigger apoptosis.
- Open Access
- 6 February 2006
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 203 (2) , 475
Correction
- 6 February 2006
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 203 (2) , 475
Open AccessCorrection